Albendazole therapy for neurocysticercosis
A prospective double‐blind trial comparing 7 versus 14 days of treatment
Citation Manager Formats
Make Comment
See Comments

Abstract
Objectiue To compare the effectiveness of two regimens of albendazole therapy for neurocysticercosis.
Design Randomized, double-blind clinical trial.
Settings Patients admitted to neurologic wards in Lima, Peru.
Patients Adult patients with active neurocysticercosis demonstrated by CT and Western blot (immunoblot).
Intervention One week (n = 25) versus 2 weeks (n = 25) of albendazole therapy.
Measurements Decrease in the number of cysts on CT.
Results Effectiveness of albendazole was 78%, with no difference between the groups when compared 3 months after therapy. Complete cure was obtained in only 38% of patients. Patients with more than 20 cysts had poorer responses to therapy. The clinical course and EEG evolution improved in most patients. Side effects were present in 38% of patients, mainly mild, transient gastrointestinal symptoms. Therapy was also associated with exacerbation of neurologic symptoms. Two patients died in the first year after therapy, both because of aggregated infections of ventricle-peritoneal shunts. One-year follow-up CT showed lesions in three of 10 patients presumed to be cured 3 months after therapy.
Conclusions Extension of albendazole therapy for more than 7 days adds no benefits for the patients.
- © 1997 by the American Academy of Neurology
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.